Herpes Zoster Vaccination in People Aged 50-59 Years.

Hongtian Li,Shichao Lu,Jianmeng Liu

DOI: https://doi.org/10.1093/cid/cir974

2012-01-01

Abstract:Herpes zoster (or shingles), an infectious disease caused by reactivation of latent varicella-zoster virus (VZV) in the dorsal root or cranial nerve ganglia, typically manifests as unilateral acute pain accompanied by a vesicular rash. The acute pain and rash usually resolve within 2– 4 weeks without treatment. Postherpetic neuralgia, commonly defined as pain that lasts .3 months after the onset of rash or cutaneous healing, is the most common and feared complication and can persist occasionally for years in some patients. In addition to postherpetic neuralgia, some patients may suffer from ocular, hearing, or other serious neurological complications [ 1 , 2 ]. Age-related decline in cell-mediated immune responses is a major risk factor of herpes zoster as well as postherpetic neuralgia. The annualized incidence of herpes zoster was 4.6, 6.9, 9.5, and 10.9 per 1000 people aged 50–59, 60–69, 70–79, and $80 years, respectively [ 3 ]; the corresponding proportion of patients who had postherpetic neuralgia in each age group was approximately 5%, 10%, 17%, and 20%, respectively [ 4 ]. People with immunosuppressive illness or those receiving immunosuppressive therapy are more vulnerable to herpes zoster and more likely to develop postherpetic neuralgia. The annualized incidence of herpes zoster was 29.4 per 1000 men seropositive for human immunodeficiency virus (HIV) and 2.0 per 1000 HIV-seronegative men [ 5 ]. Diabetes mellitus, often accompanied by altered cell-mediated immunity, was associated with an increased risk of herpes zoster and prescriptions of opioids within a year of diagnosis of shingles [ 6 ].